Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) has received an average rating of “Hold” from the nine brokerages that are covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and four have given a buy rating to the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $61.60.
TTPH has been the subject of several recent analyst reports. HC Wainwright downgraded Tetraphase Pharmaceuticals from a “buy” rating to a “neutral” rating in a report on Tuesday, September 3rd. Needham & Company LLC reissued a “hold” rating on shares of Tetraphase Pharmaceuticals in a report on Sunday, August 11th. Finally, ValuEngine downgraded Tetraphase Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, October 2nd.
A number of institutional investors have recently made changes to their positions in the business. Royce & Associates LP lifted its holdings in Tetraphase Pharmaceuticals by 10.7% during the 1st quarter. Royce & Associates LP now owns 527,900 shares of the biopharmaceutical company’s stock valued at $707,000 after purchasing an additional 51,000 shares during the last quarter. Edmond DE Rothschild Holding S.A. lifted its holdings in Tetraphase Pharmaceuticals by 90.9% during the 1st quarter. Edmond DE Rothschild Holding S.A. now owns 210,000 shares of the biopharmaceutical company’s stock valued at $281,000 after purchasing an additional 100,000 shares during the last quarter. JPMorgan Chase & Co. lifted its holdings in Tetraphase Pharmaceuticals by 803.7% during the 2nd quarter. JPMorgan Chase & Co. now owns 116,428 shares of the biopharmaceutical company’s stock valued at $56,000 after purchasing an additional 103,544 shares during the last quarter. Vanguard Group Inc. lifted its holdings in Tetraphase Pharmaceuticals by 7.4% during the 2nd quarter. Vanguard Group Inc. now owns 2,514,773 shares of the biopharmaceutical company’s stock valued at $1,208,000 after purchasing an additional 173,053 shares during the last quarter. Finally, Acadian Asset Management LLC lifted its holdings in Tetraphase Pharmaceuticals by 45.4% during the 1st quarter. Acadian Asset Management LLC now owns 560,225 shares of the biopharmaceutical company’s stock valued at $750,000 after purchasing an additional 174,939 shares during the last quarter.
Shares of NASDAQ TTPH traded up $0.03 during trading hours on Friday, hitting $3.83. The company had a trading volume of 30,667 shares, compared to its average volume of 98,911. The stock has a market capitalization of $10.06 million, a P/E ratio of -0.14 and a beta of 2.46. The company has a quick ratio of 3.95, a current ratio of 4.10 and a debt-to-equity ratio of 0.70. Tetraphase Pharmaceuticals has a 1-year low of $3.35 and a 1-year high of $54.40. The firm’s 50 day moving average is $1.42 and its 200-day moving average is $0.92.
Tetraphase Pharmaceuticals (NASDAQ:TTPH) last released its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($8.40) EPS for the quarter, missing the consensus estimate of ($7.60) by ($0.80). The company had revenue of $1.07 million during the quarter, compared to analyst estimates of $2.13 million. Tetraphase Pharmaceuticals had a negative net margin of 1,072.60% and a negative return on equity of 118.65%. On average, sell-side analysts predict that Tetraphase Pharmaceuticals will post -26.55 earnings per share for the current year.
About Tetraphase Pharmaceuticals
Tetraphase Pharmaceuticals, Inc, a biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. The company's lead product candidate is Xerava (eravacycline), a synthetic fluorocycline intravenous and IV antibiotic for use as a first-line empiric monotherapy to treat multidrug-resistant infections, including multidrug-resistant Gram-negative infections.
Read More: Conference Calls and Individual Investors
Receive News & Ratings for Tetraphase Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.